Voloridge Investment Management LLC Takes $1.25 Million Position in MEDNAX Inc (NYSE:MD)

Share on StockTwits

Voloridge Investment Management LLC purchased a new stake in MEDNAX Inc (NYSE:MD) in the third quarter, HoldingsChannel reports. The firm purchased 55,357 shares of the company’s stock, valued at approximately $1,252,000.

Several other institutional investors also recently modified their holdings of MD. Meeder Asset Management Inc. bought a new stake in MEDNAX during the 2nd quarter worth about $36,000. Benjamin F. Edwards & Company Inc. boosted its holdings in shares of MEDNAX by 56.2% in the third quarter. Benjamin F. Edwards & Company Inc. now owns 1,773 shares of the company’s stock valued at $40,000 after buying an additional 638 shares during the period. Parallel Advisors LLC increased its position in shares of MEDNAX by 78.4% during the third quarter. Parallel Advisors LLC now owns 1,993 shares of the company’s stock worth $45,000 after acquiring an additional 876 shares in the last quarter. US Bancorp DE increased its position in shares of MEDNAX by 38.5% during the second quarter. US Bancorp DE now owns 5,657 shares of the company’s stock worth $142,000 after acquiring an additional 1,572 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. acquired a new stake in shares of MEDNAX during the third quarter worth $161,000. 92.81% of the stock is owned by institutional investors and hedge funds.

In other news, Director Md Pascal J. Goldschmidt sold 5,000 shares of the firm’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $22.88, for a total value of $114,400.00. Following the completion of the transaction, the director now owns 10,821 shares in the company, valued at approximately $247,584.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 3.40% of the company’s stock.

Several research firms recently commented on MD. Zacks Investment Research raised shares of MEDNAX from a “sell” rating to a “hold” rating and set a $23.00 price objective on the stock in a research report on Monday, October 14th. TheStreet cut MEDNAX from a “c-” rating to a “d” rating in a report on Friday, November 1st. ValuEngine raised MEDNAX from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 2nd. Mizuho set a $25.00 price objective on MEDNAX and gave the stock a “hold” rating in a research report on Friday, November 1st. Finally, UBS Group decreased their price objective on MEDNAX from $19.00 to $18.00 and set a “sell” rating for the company in a report on Friday, October 18th. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $26.56.

Shares of MD opened at $25.38 on Friday. MEDNAX Inc has a 12 month low of $19.93 and a 12 month high of $39.96. The firm has a fifty day simple moving average of $25.08 and a 200 day simple moving average of $23.91. The stock has a market capitalization of $2.13 billion, a price-to-earnings ratio of 7.23, a PEG ratio of 1.01 and a beta of 0.75. The company has a current ratio of 1.93, a quick ratio of 1.93 and a debt-to-equity ratio of 1.35.

MEDNAX (NYSE:MD) last issued its quarterly earnings results on Friday, November 1st. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.08. MEDNAX had a negative net margin of 40.86% and a positive return on equity of 10.38%. The firm had revenue of $888.70 million for the quarter, compared to analyst estimates of $876.20 million. During the same period in the previous year, the business earned $0.94 EPS. The company’s revenue was down .9% compared to the same quarter last year. As a group, research analysts predict that MEDNAX Inc will post 3.04 earnings per share for the current fiscal year.

MEDNAX Profile

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.

See Also: How is net asset value different from market price?

Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX Inc (NYSE:MD).

Institutional Ownership by Quarter for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.